AgEagle Aerial Systems Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AgEagle Aerial Systems Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $13.39M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $13.74M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $19.09M | Nov 27, 2024 |
| FY2023 | Dec 31, 2021 | $9.76M | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $1.29M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $296.7K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $107.8K | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | $116.0K | Mar 28, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.64M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.29M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.46M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.22M | Nov 27, 2024 |
| FY2023 | Dec 31, 2021 | $4.26M | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $573.7K | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $94.6K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $46.1K | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | $22.7K | Mar 28, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.28M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($35.04M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($42.42M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($58.25M) | Nov 27, 2024 |
| FY2023 | Dec 31, 2021 | ($30.11M) | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | ($4.93M) | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | ($2.52M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($2.08M) | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | ($797.2K) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($13.18M) | Mar 23, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.73M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($12.64M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($39.15M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($64.28M) | Nov 27, 2024 |
| FY2023 | Dec 31, 2021 | ($30.29M) | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | ($4.93M) | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | ($2.52M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($2.06M) | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | ($666.9K) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($11.14M) | Mar 23, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.61M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $3.97M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.52M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.11M | Nov 27, 2024 |
| FY2023 | Dec 31, 2021 | $4.08M | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $29.4K | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $38.9K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Apr 13, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.96M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($6.57M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($10.96M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($19.76M) | Nov 27, 2024 |
| FY2023 | Dec 31, 2021 | ($12.46M) | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | ($2.26M) | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | ($1.82M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.78M) | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | ($328.9K) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($2.10M) | Mar 23, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.7K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $49.5K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $215.4K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $313.8K | Nov 27, 2024 |
| FY2023 | Dec 31, 2021 | $525.3K | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $106.1K | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $24.4K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $0 | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | $12.8K | Mar 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.23M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $20.58M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $25.16M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $54.18M | Nov 27, 2024 |
| FY2023 | Dec 31, 2021 | $104.68M | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $28.73M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $4.80M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $6.81M | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | $311.3K | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $7.99M | Mar 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.49M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $26.32M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $14.46M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $10.96M | Nov 27, 2024 |
| FY2023 | Dec 31, 2021 | $28.11M | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $2.37M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $521.9K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $300.4K | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.97M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | $26.47M | Mar 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.74M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($5.74M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $10.70M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $43.22M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $76.58M | Nov 27, 2024 |
| FY2023 | Dec 31, 2020 | $26.35M | Apr 4, 2023 |
| FY2021 | Dec 31, 2019 | $4.27M | Apr 12, 2022 |
| FY2020 | Dec 31, 2018 | $6.51M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | ($1.66M) | Apr 13, 2020 |
| FY2018 | Dec 31, 2016 | ($896.6K) | Mar 28, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.46M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $7.40M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $23.18M | Mar 31, 2025 |
| FY2024 | Dec 31, 2021 | $64.87M | Mar 31, 2025 |
| FY2024 | Dec 31, 2020 | $3.11M | Mar 31, 2025 |
| FY2020 | Dec 31, 2019 | $3.11M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $3.27M | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 28, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($231.23M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($218.38M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($165.58M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($111.55M) | Nov 27, 2024 |
| FY2023 | Dec 31, 2021 | ($51.05M) | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | ($20.95M) | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | ($8.20M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($5.68M) | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | ($3.60M) | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | ($87.58M) | Mar 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.61M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $819.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.35M | Nov 27, 2024 |
| FY2023 | Dec 31, 2021 | $14.59M | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | $23.94M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | $718.0K | Mar 31, 2021 |
| FY2020 | Dec 31, 2018 | $2.60M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $35.3K | Apr 13, 2020 |
| FY2018 | Dec 31, 2016 | $15.9K | Mar 28, 2019 |
| FY2017 | Dec 31, 2015 | $3.10M | Mar 23, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $4.50M | Nov 27, 2024 |
| FY2023 | Dec 31, 2022 | $893.3K | Apr 4, 2023 |
| FY2021 | Dec 31, 2021 | $1.26M | Apr 12, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (46) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (514) | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | (1) | Nov 27, 2024 |
| FY2023 | Jun 30, 2023 | (2) | Nov 27, 2024 |
| FY2023 | Mar 31, 2023 | (1) | Nov 27, 2024 |
| FY2023 | Dec 31, 2022 | (14) | Nov 27, 2024 |
| FY2017 | Dec 31, 2017 | 0 | Mar 23, 2018 |
| FY2017 | Dec 31, 2016 | (1) | Mar 23, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (46) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (514) | Mar 31, 2025 |
| FY2023 | Sep 30, 2023 | (1) | Nov 27, 2024 |
| FY2023 | Jun 30, 2023 | (2) | Nov 27, 2024 |
| FY2023 | Mar 31, 2023 | (1) | Nov 27, 2024 |
| FY2023 | Dec 31, 2022 | (14) | Nov 27, 2024 |
| FY2017 | Dec 31, 2017 | 0 | Mar 23, 2018 |
| FY2017 | Dec 31, 2016 | (1) | Mar 23, 2018 |
| FY2016 | Dec 31, 2015 | (6) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Jan 24, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 43.61M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 9.66M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 140,521 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 88.47M | Nov 27, 2024 |
| FY2023 | Dec 31, 2021 | 75.31M | Apr 4, 2023 |
| FY2021 | Dec 31, 2020 | 58.64M | Apr 12, 2022 |
| FY2020 | Dec 31, 2019 | 15.42M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 12.55M | Apr 13, 2020 |
| FY2018 | Dec 31, 2017 | 4.20M | Mar 28, 2019 |
| FY2017 | Dec 31, 2016 | 8.42M | Mar 23, 2018 |